CXCL10 and breast cancer: Furthermore, IP-10 showed highest expression in those with TNBC disease and was the most abundant CXCR3 ligand observed in all three settings (e.g. ex vivo inflamed gut-liver MPS, ex vivo metastatic liver MPS and stage IV breast cancer patients).